<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175966</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-131</org_study_id>
    <nct_id>NCT02175966</nct_id>
  </id_info>
  <brief_title>Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)</brief_title>
  <acronym>FOURward</acronym>
  <official_title>Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the combination of Daclatasvir (DCV),
      Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C
      virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation:

      Initial Therapy: Randomized Controlled Trial: Participants are assigned to intervention
      groups by chance

      Rescue Therapy: Nonrandomized Trial: Participants are expressly assigned to intervention
      groups through a non-random method such as physician choice

      Number of Arms:

      Initial Therapy: 2 Groups

      Rescue Therapy: 2 Groups
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LLOQ target detected or target not detected (LLOQ TD/TND) for each treatment arm</measure>
    <time_frame>Post-treatment Week 12</time_frame>
    <description>Sustained Virologic Response (SVR)
Hepatitis C virus (HCV)
Lower limit of quantitation (LLOQ)
Ribonucleic acid (RNA)
Target detected (TD)
Target not detected (TND)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On-treatment safety, as measured by frequency of deaths, SAEs, discontinuations due to AEs, and Grade 3/4 laboratory abnormalities (hematologic and liver function, based on DAIDs criteria) by each arm and overall</measure>
    <time_frame>Up to post-treatment week 4</time_frame>
    <description>Serious AE (SAE)
Adverse Event (AE)
Division of AIDs (DAIDS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TD/TND</measure>
    <time_frame>Weeks 1, 2, 4 and 6 (Arm 2 only); post-treatment Weeks 2 (SVR2), 4 (SVR4) and 24 (SVR24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TND</measure>
    <time_frame>Weeks 1, 2, 4 and 6 (Arm 2 only); and post-treatment Weeks 2, 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each arm achieving SVR12 associated with HCV geno subtype 1a vs 1b</measure>
    <time_frame>Post-treatment Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each arm achieving SVR12 associated with interleukin-28B (IL28B) rs12979860 SNP status (CC genotype or non-CC genotype)</measure>
    <time_frame>Post-treatment Week 12</time_frame>
    <description>Single nucleotide polymorphism (SNP)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325+Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial Therapy:
Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks
Sofosbuvir 400 mg tablet once daily orally for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial Therapy
Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks
Sofosbuvir 400 mg tablet once daily orally for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks
Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sofosbuvir 400 mg tablet once daily orally for 12 weeks
Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV/ASV/BMS-791325</intervention_name>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325+Sofosbuvir</arm_group_label>
    <arm_group_label>Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir</arm_group_label>
    <arm_group_label>Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a</arm_group_label>
    <arm_group_label>Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <arm_group_label>Arm 1: DCV/ASV/BMS-791325+Sofosbuvir</arm_group_label>
    <arm_group_label>Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir</arm_group_label>
    <arm_group_label>Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a</arm_group_label>
    <other_name>Sovaldi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon α-2a</intervention_name>
    <arm_group_label>Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a</arm_group_label>
    <arm_group_label>Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Males and Females ≥18 years of age, inclusive

          -  Chronic HCV infection Genotype 1 only

          -  Non-cirrhotic

          -  Treatment naive subjects with no previous exposure to an Interferon formulation (ie,
             IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease,
             polymerase inhibitor, etc.)

        Exclusion Criteria:

          -  HCV Genotype other than Genotype 1

          -  Documented or suspected hepatocellular carcinoma

          -  Evidence of decompensated liver disease

          -  Contraindication(s) to Peg/RBV therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School Of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health - University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <disposition_first_submitted>March 22, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 23, 2017</disposition_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

